Oncology Venture A/S management team
Peter Buhl Jensen
Chief Executive Officer
Buhl Jensen, born 1955, is CEO of Oncology Venture A/S since 2012.
Buhl Jensen has a strong combination of commercial experience and expertise in the field of oncology. Buhl Jensen has founded and was previously CEO of TopoTarget A/S. Buhl Jensen was instrumental in TopoTarget’s stock exchange listing in 2005 and secured EMA and FDA approval of the company’s first product, Savene©/Totect©.
Buhl Jensen is also behind the development of the pharmaceutical drug Belinostat, which was approved by the FDA in the summer of 2014.
Buhl Jensen has managerial experience from TopoTarget, where he managed approx. 140 employees and Aalborg Hospital where he was a senior consultant at the Department of Oncology and led approx. 280 employees.
Number of shares: Buhl Krone Holding (80 % owned by Peter Buhl Jensen) owns a total of 5 187 516 shares in Oncology Venture A/S.
Number of warrants: 315 000.
Ulla Hald Buhl
Chief Operating Officer
Hald Buhl, born 1964, is COO of Oncology Ventures A/S since 2012.
Hald Buhl has a broad background in clinical trials, organisation management and communications. Hald Buhl has previously been in charge of TopoTarget A/S’s investor relations department and is currently active in this area in both Swedish WNT Research AB (listed on AktieTorget) as well as Danish Medical Prognosis Institute A/S (listed on NASDAQ First North in Copenhagen).
During 1999-2001, Hald Buhl worked as a Team Leader in oncology at AstraZeneca A/S and during 2001-2005 Hald Buhl was the head of the regulatory department of TopoTarget A/S.
Number of shares: Buhl Krone Holding (20 % owned by Ulla Hald Buhl) owns a total of 5 187 516 shares in Oncology Venture A/S.
Number of warrants: 104 180.
Chief Technology Officer
Thomas Jensen, born 1978, is pioneering the bridging of: good science, effective laboratory techniques and bioinformatics to advance the biology of cancer. He founded & leads Oncology Venture’s laboratories in Denmark and in the USA. Along side nurturing our global laboratories, he is instrumental in building our investor relations, securing operational financing and fostering business growth of Oncology Venture.
Amongst Thomas’ accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing.This allows for high resolution analysis of cancer patients’ biopsies. His inventions are an important foundation of the DRP® -Drug Response Prediction platform. Thomas Jensen co-founded Oncology Venture in 2004.
Number of shares: 713 620.
Number of warrants: 916 040.
Chief Scientific Officer
Steen, born 1961, is the founder of Oncology Venture A/S and the inventor of DRP™, the Drug Response Prediction Platform which is Oncology Venture’s core technology and science platform. Knudsen is a Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. Steen Knudsen founded Oncology Venture in 2004.
Number of shares: 6 168 680.
Number of warrants: 0.
Chief Financial Officer
Niels Laursen, born 1956, has profound experience within public Danish and international biotech ventures, which has given him a very good knowledge within financial issues. Furthermore Mr. Niels Laursen is experienced in management, strategy development, implementation and change management. Niels has been the CFO of Oncology Venture A/S since 2014.
Number of shares: 75 278.
Number of warrants: 149 820.
Claus Frisenberg Pedersen
Chief Commercial Officer
Frisenberg Pedersen, born 1972, is Chief Commercial Officer of Oncology Venture Aps since 2018.
Frisenberg Pedersen has a strong back-ground in developing and executing corporate strategies from a broad array of companies and industries. Further, Frisenberg Pedersen has an extensive experience from developing financial and brand value for the companies he works with. Prior to joining Oncology Venture Frisenberg Pedersen held the position as CEO of ECCO Shoes in Northern Europe for 5 years, where he was instrumental in developing ECCO’s global blue print for retail Joint Ventures, and also played a key role in re-positioning the perception of the ECCO brand in Northern Europe.
In his previous career Frisenberg Pedersen was partner in the strategy consulting firm Qvartz, and as such have advised many companies and private equity firms on topics like strategy, commercialization, brand development, retail expansion, sales management and general value creation.
Frisenberg Pedersen currently takes up board positions in a number of external companies, within his areas of expertise.
Number of shares: 622 385.
Number of warrants: 0.